Cloning and Initial Characterization of Mouse Meltrin beta  and Analysis of the Expression of Four MetalloproteaseDisintegrins in Bone Cells*

Daisuke InoueDagger §, Martha Reid, Lawrence Lum, Jörn Krätzschmarpar , Gisela Weskamp, Yoon Mo MyungDagger , Roland BaronDagger , and Carl P. Blobel**

From the Dagger  Department of Orthopaedics and Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510 and the  Cellular Biochemistry and Biophysics Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Here we report the cloning and initial biochemical characterization of the mouse metalloprotease/disintegrin/cysteine-rich (MDC) protein meltrin beta  and the analysis of the mRNA expression of four MDC genes (meltrin alpha , meltrin beta , mdc9, and mdc15) in bone cells, including osteoclasts and osteoblasts. Like most other MDC proteins, the predicted meltrin beta  protein consists of a signal sequence, prodomain, metalloprotease domain with a predicted catalytic site, disintegrin domain, cysteine-rich region, epidermal growth factor repeat, transmembrane domain, and cytoplasmic domain with putative signaling motifs, such as potential SH3 ligand domains. Northern blot analysis indicates that meltrin beta  is widely expressed, with the highest expression in bone, heart, and lung. RNase protection studies revealed expression of all four MDC genes analyzed here in osteoblasts, whereas only mdc9 and mdc15 mRNAs were detectable in osteoclast-like cells generated in vitro. Treatment of primary osteoblasts with 10 nM calcitriol increased meltrin beta  expression more than 3-fold, and both meltrin alpha  and meltrin beta  expression is apparently regulated in a differentiation-associated manner in a mouse osteoblastic cell line, MC3T3E1. Collectively, these results suggest that meltrin alpha  and meltrin beta  may play a role in osteoblast differentiation and/or function but are not likely to be involved in osteoclast fusion.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Proteins containing a metalloprotease domain, a disintegrin domain, and a cysteine-rich region (MDC1 proteins, also referred to as ADAMs (1)) are a family of membrane-anchored glycoproteins that are related to soluble snake venom metalloproteases and integrin ligands. MDC proteins have been implicated in a variety of important cellular processes, including sperm-egg and muscle cell membrane binding and fusion (2-6); in neuronal induction, lateral inhibition, and neuronal outgrowth in Drosophila (7-9); and in the release of the membrane-anchored cytokine tumor necrosis factor alpha  (10, 11). The finding that the tumor necrosis factor alpha  convertase is an MDC protein (10, 11) and that Drosophila Kuzbanian may be involved in the intracellular processing Notch (9, 12) raises the intriguing possibility that other membrane-anchored proteins are also processed and/or released by metalloprotease-disintegrin proteins (13). Because several MDC proteins contain potential cytoplasmic signaling motifs, including SH3 ligand domains (1, 14-16), MDC proteins may also play a role in signaling events, or they may be regulated through interactions with cytoplasmic proteins. At present, over 20 genes encoding MDC proteins have been identified in different species, including Caenorhabditis elegans (17), Drosophila melanogaster (7, 8), Xenopus laevis (18, 19), mice (1, 6, 14, 20, 21), guinea pigs (1, 4, 21, 22), and humans (10, 11, 14, 15, 23). Although the function of many of these proteins remains to be determined, it is clear that different MDC proteins are capable of performing a variety of important tasks.

To date, MDC proteins have been implicated in two distinct membrane binding and fusion events. Fertilin, which functions in sperm-egg binding and fusion, is a heterodimeric complex of two MDC proteins, fertilin alpha  and fertilin beta . A monoclonal antibody against fertilin beta  blocks sperm-egg fusion (2), as do peptides corresponding to the predicted integrin binding sequence of fertilin (5, 24-26). On the egg, an alpha 6beta 1 integrin has been identified as a receptor for sperm, and thus as a candidate receptor for fertilin (25). In C2C12 mouse muscle cells, an MDC protein called meltrin alpha  has been found to play a role in the membrane fusion event that gives rise to multinucleated myotubes (6). The involvement of MDC proteins in sperm-egg fusion and in muscle cell fusion suggests that MDC proteins are closely linked to the process of membrane fusion, either by mediating a prerequisite binding or signaling step, or by directly triggering the membrane fusion event via a predicted fusion peptide (27).

In this study, we report the cDNA cloning, sequencing, and initial biochemical characterization of the mouse MDC protein meltrin beta . Because the highest expression of meltrin beta  in adult mice was previously reported in bone (6), we further investigated the expression of meltrin beta  and of the three other metalloprotease-disintegrins, meltrin alpha , mdc9, and mdc15 (metargidin), in osteoblasts and osteoclasts. Our results demonstrate that all four MDC genes are expressed in osteoblasts and that the expression of meltrin beta  is inducible by 1alpha ,25-dihydroxycholecalciferol (calcitriol). Furthermore, expression of meltrin alpha  and meltrin beta  appears to be regulated during osteoblast differentiation. Neither meltrin alpha , which has been implicated in muscle fusion, nor meltrin beta  is detectable in in vitro-generated osteoclast-like cells (OCLs), which arise from the fusion of mononuclear precursors of the monocyte/macrophage/osteoclast lineage. Therefore, we conclude that Meltrin alpha  and Meltrin beta  may not play a role in osteoclast fusion but instead are more likely involved in osteoblast differentiation and/or osteoblast activity in bone.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

cDNA Cloning of Meltrin alpha  and Meltrin beta -- mRNA from ~20% fused mouse C2C12 cells (28) was used to synthesize a cDNA library, utilizing the Stratagene ZAP cDNA library synthesis kit (according to the manufacturer's instructions; see also Ref. 29). The unamplifed cDNA library was screened under high stringency conditions with a [alpha -32P]dCTP-labeled cDNA probe for meltrin beta , which was generated as follows: nested reverse transcription-PCR was performed on C2C12 cDNA (see above) with the following primers designed from the published partial meltrin beta  sequence (6): primer 1 (sense primer), GAGGAATGT GACTGTGGAGA; primer 2 (sense primer), GTGACCTCCC CGAGTTCTGC; and primer 3 (antisense primer), CAGTTTCCAT AGGTGTCACC. Primers 1 and 3 were used in a primary reaction, which was diluted 1:400 and used as template for a secondary reaction with primers 2 and 3, performed in the presence of [alpha -32P]dCTP. Using this probe, 20 positive cDNA clones were identified from 106 plaques screened. A PCR analysis with the pBluescript vector-specific T3 primer (Stratagene), and a 5' antisense primer (TTCAGAGCCA CGTTGGAGGC), designed from the previously published partial meltrin beta  sequence (6), was carried out to find the clone with the longest 5' extension. The longest clone thus identified was subjected to in vitro excision, sequenced completely on both strands using a primer walk approach, and found to have a cDNA insert of 6413 base pairs. The initial methionine residue of the deduced meltrin beta  protein sequence is followed by a hydrophobic predicted signal sequence and an apparently full-length open reading frame encoding a protein with 920 amino acid residues. Analysis of the mouse meltrin beta  cDNA and translated protein sequences was performed using MacVector sequence analysis software (Kodak Scientific Imaging Systems), and the alignment and hydrophobicity plot was generated using DNASTAR software (Megalign and Protean program modules).

Using the same approach, meltrin alpha  cDNA was cloned from the library as a template to make cRNA for RNase protection studies (see below). The following PCR primers were used in a nested reaction to generate the [alpha -32P]dCTP labeled cDNA probe, which corresponds to nucleotides 298-500 of the meltrin alpha  sequence cited in Ref. 6 (GenBank accession no. D50411): primer 1 (sense primer), ATGGCAGAGC GCCCGGCGCG; primer 2 (sense primer), CGTGCAGCCC GAGGGATGAG; primer 3 (antisense primer), CATTGGCAAT GAGTCCCTCA; and primer 4 (antisense primer), AGTGAGAGAG ACATCAGTAC. Primers 1 and 4 were used in a primary reaction, which was subsequently diluted 1:400 and used as template for a secondary reaction with primers 2 and 3, performed in the presence of [alpha -32P]dCT. The resulting labeled cDNA probe was used to isolate two cDNA clones for meltrin alpha  out of 106 plaques screened. One of the cDNA clones contained an open reading frame that was judged to be full-length based on the presence of the meltrin alpha  signal sequence, as determined by sequencing the 5' end of both clones with the vector-specific T3 primer (Stratagene).

RNA Analysis-- Mouse tissue Northern blots were obtained from CLONTECH and probed with a PCR-generated 32P-labeled mouse meltrin beta  cDNA under high stringency conditions as described previously (20). For RNase protection assays, total RNA was extracted from various bone cells according to the previously described method (30), and the concentrations were determined by spectrophotometry. To prepare cRNA probes, cDNA fragments of mouse mdc9 (an XhoI/EcoRI fragment from nucleotide 106 to nucleotide 309 (14)), meltrin alpha  (an AflII/HindIII fragment from nucleotide 842 to nucleotide 1091 (6)), meltrin beta  (a HindIII/BamHI fragment from nucleotide 2883 to nucleotide 3210), mouse mdc15 (an AflII/EcoRI fragment from nucleotide 727 to nucleotide 1074; GenBank accession no. AF006196), the calcitonin receptor (from nucleotide 1156 to nucleotides 1677 (31)) and GAPDH (from nucleotide 521 to nucleotides 660) were subcloned into the appropriate sites in a pBluescript II vector (Stratagene) and transcribed in vitro in the antisense direction by T7 or T3 RNA polymerase in the presence of [alpha -32P]UTP. Cold UTP was also added to the reaction for GAPDH to reduce the specific activity of the probe to approximately one tenth. Multiprobe RNase protection assays were performed using RPA II kit (Ambion, Inc., Woodward, TX) according to the protocol suggested by the supplier. 10 µg of total RNA was incubated with two or more labeled cRNA probes (20,000-50,000 cpm per reaction for each probe) in a single tube at 42 °C for 16 h. After digesting single-stranded RNA with a mixture of RNase A (5 units/ml) and RNase T (200 units/ml) at 37 °C for 30 min, protected RNA fragments were precipitated, resolved on a 5% denaturing polyacrylamide gel, and visualized by autoradiography.

Antibodies-- Two New Zealand White rabbits were immunized using a GST fusion protein with the N-terminal half of the meltrin beta  cytoplasmic domain (amino acid residues 728-817), and two rabbits were immunized with a GST fusion protein with the C-terminal half of the cytoplasmic tail (corresponding to amino acid residues 818-920). The fusion protein expression constructs were assembled using PCR primers with added restriction sites to allow in-frame cloning into the pGEX/4T-3 GST fusion vector (Pharmacia LKB). Antibodies were raised by Animal Pharm (Healdsburg, CA) according to established protocols (32).

Cell Cultures-- A murine macrophage cell line, IC21, was obtained from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. C2C12 cells (28) were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 2% chick embryo extract (growth medium) for 2 days, and myogenic differentiation and fusion were induced by adding Dulbecco's modified Eagle's medium with 2% horse serum (Life Technologies, Inc.). A murine osteoblastic cell line, MC3T3E1 (33), was a generous gift from Dr. R. T. Franceschi (University of Michigan, Ann Arbor, MI), and was grown in alpha -minimum Eagle's medium containing 10% fetal bovine serum. Primary osteoblastic cells were isolated from calvariae of newborn CD1 mice (Charles River Laboratories, Wilmington, MA) by digestion with 0.1% collagenase type IA (Sigma) and 0.2% dispase (Boehringer Mannheim) as described previously (34). Bone marrow cells were obtained from tibiae and femurs of 8-12-week-old CD1 mice (Charles River Laboratories). To generate OCLs in vitro, 2 × 107 marrow cells were cocultured with 2 × 106 primary osteoblasts in a 10-cm culture dish in the presence of 10 nM 1alpha ,25-dihydroxycholecalciferol (calcitriol) (34). After 6 days, cells were treated sequentially with 0.1% collagenase/0.2% dispase and 5 mM EDTA to remove osteoblastic cells; OCLs remained strongly attached to the culture dish. These OCLs have virtually all of the characteristics of authentic osteoclasts, such as the ability to resorb bone, and the expression of lineage-specific markers, including tartrate-resistant acid phosphatase, a specific marker for cells of the osteoclast lineage (35), and the calcitonin receptor (36). In this coculture system, formation of OCLs is totally dependent on the presence of calcitriol. In every preparation, more than 80% of the OCL-enriched population was positively stained for tartrate-resistant acid phosphatase.

Expression of Meltrin beta  in COS-7 Cells-- A pcDNA3 expression vector (Invitrogen) for meltrin beta  was constructed by subcloning an EcoRI/HindIII fragment, which contains the full-length meltrin beta  open reading frame. The EcoRI site is part of the 5' linker sequence in a lambda  ZAP library, and the HindIII site is at nucleotide 2883, just downstream of the meltrin beta  stop codon at nucleotide 2808. The meltrin beta  pcDNA3 expression vector, or an identical control vector without an insert, were used to transfect COS-7 cells using LipofectAMINE reagent as a delivery vehicle (Life Technologies, Inc.). The transiently transfected cells were harvested after 3 days in tissue culture, and expression of meltrin beta  was monitored by Western blot analysis as described below.

Western Blot Analysis-- Protein A-purified IgG was isolated from antisera raised against GST fusion proteins with either the C-terminal or the N-terminal part of the meltrin beta  cytoplasmic domain (see above). Meltrin beta -specific antibodies were affinity-purified using the appropriate fusion protein coupled to CNBr-activated Sepharose CL4B (Pharmacia LKB, coupling performed according to the manufacturer's instructions). The IgG sample that remained after affinity purification and had effectively been depleted of meltrin beta -specific antibodies was used as a control for some Western blots. The affinity-purified IgG, the control IgG, and the complete antiserum and preimmune antiserum were tested by Western blot analysis on COS-7 cells expressing meltrin beta  from a pcDNA3 vector or on control COS-7 cells transfected with pcDNA3 vector lacking an insert. The affinity-purified and control antibodies were also used on a lysate of C2C12 mouse myoblasts that included about 20% fused multinucleated cells. The Western blot of a primary osteoblast (POB) lysate was probed with immune or preimmune serum at a 1:500 dilution, which produced a stronger signal than the affinity-purified antibodies under the conditions used here. All cells were lysed at a concentration of 4 × 106/ml in cell lysis buffer (1% Nonidet P-40 in PBS and protease inhibitors (3)). Following lysis, nuclei were removed by spinning at 13,000 rpm in a Sorvall tabletop centrifuge for 15 min at 4 °C. COS-7 cell lysates devoid of nuclei were mixed with 2× sample loading buffer immediately, whereas C2C12 and POB lysates were incubated with 100 µl of Concanavalin A-Sepharose (Pharmacia, LKB) per 1 ml extract for 1 h at 4 °C to enrich for glycoproteins. Bound glycoproteins were eluted in 1× sample buffer after three washes in cell lysis buffer. Prior to electrophoresis, all samples were denatured and reduced by heating at 95 °C for 5 min in the presence of 50 mM dithiothreitol and subsequently alkylated by incubation with 100 mM iodo-acetic acid. Proteins were separated by SDS-polyacrylamide gel electrophoresis (37) and transferred to nitrocellulose (Schleicher & Schuell) using a semidry blotting apparatus (E&K, Saratoga, CA). Blotted protein samples were blocked in 5% nonfat dry milk dissolved in PBS, incubated in primary and secondary antibody in PBS, 0.05% Tween 20, washed in PBS, 0.5% Tween. Bound antibodies were visualized using a horseradish peroxidase-coupled secondary antibody according to the manufacturer's instructions (Promega) in combination with a chemiluminescence detection system (ECL, Amersham Corp.) and Kodak XAR autoradiography film (Eastman Kodak Co.). In initial tests for specificity on Western blots of meltrin beta -transfected COS-7 cells, all four antisera (two each raised against the C-terminal and the N-terminal half of the meltrin beta  cytoplasmic tail) recognized a band of 115 kDa (data not shown), in addition to other, faster migrating bands. These bands were not visible on blots of COS-7 cells transfected with the vector alone. For all Western blots presented here, antibodies raised against the C-terminal part of the meltrin beta  cytoplasmic tail from one of the two rabbits were used, because these antibodies reacted with the least number of nonspecific bands (defined as bands that were also present in nontranfected COS-7 cell lysates or as bands that were not recognized by all four antisera).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

cDNA Cloning and Sequence of Meltrin beta -- A cDNA clone coding for full-length mouse Meltrin beta  was first isolated from a mouse C2C12 muscle cell library, using a PCR-generated cDNA fragment as a probe (see "Materials and Methods") and then sequenced using a primer walk approach. This clone had an insert of 6413 base pairs, with an open reading frame of 2760 base pairs, 35 base pairs of 5' untranslated sequence, and 3618 base pairs of 3' untranslated sequence. The meltrin beta  protein sequence, as deduced from the open reading frame, predicts a protein of 920 amino acid residues with four sites of N-linked glycosylation. The sequence of Meltrin beta  contains all protein modules that are characteristic of members of the MDC protein family: a signal sequence is followed by a prodomain, a metalloprotease domain with a predicted catalytic site consensus sequence (HEIGHNFGMSHD), a disintegrin domain, a cysteine-rich region, an epidermal growth factor-like repeat, a transmembrane domain, and a cytoplasmic tail. Like several other MDC proteins, such as MDC9 (14), meltrin alpha  (6), MDC15 (15, 16), and the tumor necrosis factor alpha convertase (10, 11), the cytoplasmic tail harbors potential signaling motifs that include proline-rich predicted SH3 ligand sequences. The sequence of Meltrin beta  is shown in Fig. 1A in an alignment with the two most closely related MDC proteins presently known, meltrin alpha  and ADAM 13. The hydrophilicity plot of Meltrin beta  (Fig. 1B) predicts an N-terminal hydrophobic signal sequence and a transmembrane domain between amino acid residues 707 and 725. After removal of the predicted signal sequence, Meltrin beta has a deduced molecular mass of 99.23 kDa.


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment of mouse meltrin alpha , X. laevis ADAM 13, and mouse meltrin beta  and hydrophilicity plot of meltrin beta . A, a mouse meltrin beta  cDNA was cloned and sequenced as described under "Materials and Methods," and the deduced protein sequence was aligned with the published protein sequences of the two most closely related MDC proteins, mouse meltrin alpha  (6) and X. laevis ADAM 13 (18). The alignment was generated using the Megalign module of the DNAstar sequence analysis software. Amino acid residues present in at least two of the three proteins are boxed. The sequence similarity was found to be 41.9% between mouse meltrin beta  and X. laevis ADAM 13, 40.4% between mouse meltrin alpha  and meltrin beta , and 39.0% between mouse meltrin alpha  and ADAM 13 (values calculated with DNAstar Megalign software, using a PAM 250 residue weight table). The predicted signal sequence cleavage site of meltrin beta  is indicated by an arrowhead, and the predicted boundaries of the different protein domains are indicated and labeled. The metalloprotease catalytic site consensus sequence is surrounded by a box with a hatched outline, and predicted N-linked glycosylation sites are marked by an asterisk. B, the hydrophilicity plot of meltrin beta  was generated using the Protean module of the DNAstar sequence analysis software.

Analysis of the Tissue Distribution of Meltrin alpha , Meltrin beta , mdc9, and mdc15 and of the Expression in Bone Cell Cultures in Vitro-- By Northern blot analysis, meltrin beta  mRNA expression can be detected in all adult mouse tissues examined, with the highest expression in heart and lung, followed by brain and spleen and then by relatively low expression in liver, skeletal muscle, kidney, and testis (Fig. 2). Analysis by RNase protection assays revealed that meltrin alpha  mRNA is also expressed in various tissues, including brain, heart, kidney, liver, lung, and skeletal muscle (see Fig. 4; some data not shown). Because the highest expression of meltrin alpha  and meltrin beta  in adult mouse tissues was observed in bone (see Fig. 4; some data not shown), confirming the data from a previous report (6), we attempted to determine which cell types in bone express the mRNA coding for these proteins by RNase protection analysis. For comparison, we also examined mRNA levels of two other MDC genes, mdc9 and mdc15, which are both widely expressed. As primary cell materials, we utilized POBs isolated from newborn mouse calvariae and OCLs generated in vitro by cocultures of POBs and bone marrow cells. First, to investigate whether expression of meltrin alpha  and meltrin beta  is associated with osteoclast differentiation, we examined the expression in cocultures in the absence or presence of calcitriol, which is a strong inducer of osteoclast differentiation (36). As shown in Fig. 3A, an osteoclast-specific marker, the calcitonin receptor, was only detectable in cocultures treated with calcitriol and in purified OCLs, thus verifying the integrity and fidelity of the mRNA samples. Interestingly, mRNA expression of meltrin beta , and to a lesser extent of meltrin alpha , in cocultures was up-regulated by treatment with calcitriol. However, neither meltrin alpha  nor meltrin beta  was detectable in purified mature OCLs. When we analyzed mRNA from POBs cultured alone in the absence or presence of calcitriol, we found abundant expression of both meltrin alpha  and meltrin beta  in the POB cultures and a 3.6-fold induction in the steady state level of meltrin beta  mRNA by calcitriol (Fig. 3A and Table I). Consistent with the absence of meltrin alpha  and meltrin beta  messages in purified OCLs, a macrophage cell line, IC21, also lacked the expression of meltrin alpha  and meltrin beta . These results suggest that meltrin alpha  and meltrin beta  are not appreciably expressed in the monocyte/macrophage/osteoclast lineage and that their expression is restricted to cells of mesenchymal origin such as osteoblasts and myoblasts. The fact that the level of meltrin alpha  and meltrin beta  expression in cultured POBs is much higher than that in the whole bone (Fig. 4) also supports the idea that the osteoblast is the major cell type expressing these two MDC genes. However, because heterogeneous primary cultures were used in this study, we cannot exclude the possibility that meltrin alpha  and meltrin beta are expressed in early osteoclast precursors and other hematopoietic cells. Taken together with the calcitriol effects on POBs, these results indicate a correlation between meltrin alpha  and meltrin beta expression and osteoblast differentiation.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 2.   Northern blot analysis of meltrin beta  expression in adult mouse tissues. A mouse tissue Northern blot (CLONTECH) was probed with alpha -32P-labeled meltrin beta  cDNA, or as a control with beta -actin cDNA, under high stringency conditions. The size of the major meltrin beta  mRNA was found to be approximately 6.5 kilobases, indicating that the meltrin beta  cDNA clone of 6.4 kilobases is likely to be full-length. The highest expression level of meltrin beta  mRNA was observed in heart and lung, followed by brain, spleen, testis, kidney, skeletal muscle, and liver. A band of just under 9 kilobases was also detected in heart and liver, which may be a splice variant of meltrin beta .


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 3.   RNase protection analysis of the mRNA expression of four MDC genes in bone cells. A, 10 µg of total RNA obtained from various bone cells was analyzed for expression of the calcitonin receptor, meltrin alpha , meltrin beta , and GAPDH by RNase protection assays as described under "Materials and Methods." Performance of each cRNA probe was verified separately prior to the multiprobe analysis. Undigested free probes are shown in the first four lanes. The following abbreviations were used to label the lanes: tRNA, yeast tRNA control; POB, primary osteoblasts cultured for 6 days in the presence (+D) or absence (-D) of 10 nM calcitriol; CoC, cocultures of POBs and bone marrow cells on day 6 with (+D) or without (-D) 10 nM calcitriol; OCL, osteoclast-like cells. Protected RNA fragments are indicated by arrowheads. Expression of mdc15 (B) and of mdc9 mRNA (C) in bone cells was examined in the same way as described for A). Free probes are shown in the first two lanes in each panel.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of densitometric analysis for fold induction of expression of the four MDC mRNAs by calcitriol
Induction of mRNA expression of the four MDC genes by calcitriol was quantitated by densitometry using autoradiograms obtained by RNase protection analysis (a representative result is shown in Fig. 3). Data was corrected for GAPDH and shown as fold induction. The number of data collected from independent experiments is shown as "n." For meltrin beta  and meltrin alpha , data are expressed as mean ± S.D. For mdc9 and mdc15, values obtained from two separate experiments are shown.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 4.   Temporal profile of expression of meltrin alpha  and meltrin beta  during osteoblast differentiation. 10 µg of total RNA each obtained from mouse tissues, POBs, and MC3T3E1 cells was analyzed for expression of meltrin alpha , meltrin beta , and GAPDH by RNase protection assays as described under "Materials and Methods." For the time course experiments, MC3T3E1 cells were cultured for 3 weeks with medium changes every 2 or 3 days, and the cells were harvested for RNA analysis at various time points as indicated at the top of each lane (in days). For each time point, medium was changed 1 day before the time point. For comparison between bone and the other tissues, a relatively shorter exposure is shown here. In an autoradiogram exposed longer, both meltrin alpha  and meltrin beta were clearly visible in brain and heart (not shown).

To further address this issue, we analyzed the temporal profile of meltrin alpha  and meltrin beta  expression in long term cultures of a mouse calvariae-derived osteoblastic cell line, MC3T3E1. It has been shown that this cell line is able to progressively differentiate into mature osteoblast-like cells that produce mineralized matrix in vitro. As shown in Fig. 4, MC3T3E1 cells expressed a fairly high level of meltrin alpha  and meltrin beta  mRNA at the proliferative stage (day 1). Immediately after the cells became confluent (day 4), the expression of the two genes was down-regulated, and from this point, a relatively low level of expression was maintained throughout the remaining culture period (days 4, 8, and 21). Interestingly, meltrin alpha  expression showed a slight but reproducible increase at later stages (days 8 and 21). Thus, both meltrin alpha  and meltrin beta  are apparently predominantly expressed in cells of the osteoblast lineage in bone, and the expression of these genes in the osteoblast-like cell line MC3T3 E1 is dependent on the stage of differentiation.

Similar analysis of mdc9 and mdc15 revealed expression in both of the bone cell types analyzed, i.e. in osteoblasts and osteoclasts (Fig. 3, B and C). These results are consistent with previous findings that these two genes are ubiquitously expressed (14, 15). Interestingly, we found that the steady state levels of mdc9 and mdc15 mRNA in cocultures were slightly but consistently up-regulated by treatment with calcitriol, whereas the same treatment had no effect on POB cells (Fig. 3 and Table I). These results suggest that calcitriol increased expression of mdc9 and mdc15 in hematopoietic cells derived from bone marrow, most likely in cells of the osteoclast lineage, although the increased expression may also be due to nonosteoclastic cells present in the primary cell cocultures containing various other cells that may respond to vitamin D treatment. Because the level of expression in purified mature OCLs was relatively lower than that observed in cocultures (Fig. 3, B and C), one interpretation is that the up-regulation of mdc9 and mdc15 mRNA expression by calcitriol correlates with an early stage of osteoclast differentiation.

Western Blot Analysis of Meltrin beta -- One of the questions raised by the domain structure of MDC proteins is how the domains are processed to yield a functional protein. To assess any potential proteolytic processing of Meltrin beta , we raised antibodies in rabbits against GST fusion proteins with different parts of the Meltrin beta  cytoplasmic tail (see "Materials and Methods"). Probing Western blots of reduced and alkylated extracts from COS-7 cells transfected with meltrin beta  with affinity-purified anti-Meltrin beta  cytoplasmic tail antibodies (see "Materials and Methods") revealed bands of 115, 87, 42, and 35 kDa (Fig. 5, lane 1). These bands appear to be specific for Meltrin beta , as they are not recognized by control antibodies depleted of Meltrin beta  reactive IgG (Fig. 5, lane 2) and are not seen when COS-7 cells that have been transfected with the expression vector alone are probed with the affinity-purified antibodies (Fig. 5, lane 3). On a Western blot of extracts from primary osteoblasts probed with the Meltrin beta  antiserum, bands of 115, 87, and 42 kDa and some minor bands close to 35 kDa are visible (Fig. 5, lane 4); these bands are not recognized by preimmune serum (Fig. 5, lane 5). This band pattern closely resembles the pattern observed in COS-7 cells expressing Meltrin beta  (Fig. 5, lane 1) When an extract of ~20% fused C2C12 mouse myoblasts was probed with the affinity-purified Meltrin beta  IgG, a band of 115 kDa and weaker bands of 110 and 42 kDa were visible (Fig. 5, lane 6); these bands were not present in an identical sample probed with the control IgG (Fig. 5, lane 7). These results suggest that a majority of Meltrin beta  is present in a form that most likely includes the prodomain, although POB cells apparently contain a significant amount of an 87-kDa Meltrin beta  band that presumably lacks the prodomain. The faster migrating bands likely correspond to processed forms of the protein in all three cell types examined here, although these bands could conceivably also arise due to cross-reactivity of the antibodies with other proteins, including related MDC proteins.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 5.   Western blot analysis of meltrin beta . Extracts of COS-7 cells expressing Meltrin beta  (lanes 1 and 2), COS-7 cells transfected with the pcDNA expression vector (lane 3), primary osteoblasts (lanes 4 and 5), and C2C12 mouse myoblasts (lanes 6 and 7) were probed with affinity-purified Meltrin beta  cytoplasmic tail antibodies (lanes 1, 3, and 6), control antibodies depleted of Meltrin beta reactive IgG (lanes 2 and 7), or whole Meltrin beta  antiserum at a 1:500 dilution (lane 4) and with preimmune serum at a 1:500 dilution (lane 5).

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Proteins containing a metalloprotease domain, a disintegrin domain, and a cysteine-rich region (MDC proteins) have been implicated in a variety of important cellular processes, including neurogenesis (7, 8), protein ectodomain shedding (10, 11), and cell-cell binding and fusion (2, 4, 6). According to a previous report, an MDC protein termed meltrin alpha  (also referred to as ADAM 12 (1)) has been shown to play a critical role in C2C12 myoblast fusion (6). Furthermore, both meltrin alpha , and a second MDC protein of unknown function termed meltrin beta  were shown to be most abundantly expressed in adult bone, and in neonatal muscle (6), which was confirmed in the present study. Because bone also contains fusing cells, i.e. multinucleated osteoclasts, these observations raised the possibility that meltrin alpha  and/or meltrin beta  may be expressed in cells of the osteoclast lineage and may therefore be involved in the fusion process of these cells. However, our results indicate that in bone, both meltrin alpha  and meltrin beta  are primarily expressed in cells of the osteoblast lineage but cannot be detected in mature osteoclasts by the relatively sensitive method of RNase protection. We also found that meltrin alpha  and meltrin beta  are widely expressed in other tissues at various levels, implying that both meltrins may exert divergent functions in different types of cells, including myoblasts and osteoblasts.

In this study, the full-length cDNA of mouse meltrin beta  has been cloned and sequenced. Of the presently known MDC proteins, X. laevis ADAM 13 (18) and Meltrin alpha  (6) are most closely related to Meltrin beta . X. laevis ADAM 13 is localized to somatic mesoderm and cranial neural crest cells from gastrulation through neurulation and tail bud stages and has therefore been suggested to function in neural crest adhesion and migration and in myoblast differentiation (18). From the sequence similarity between Meltrin beta  and X. laevis ADAM 13 (41.9%) it can not be judged whether these two proteins are orthologues, and further study will be necessary to compare the developmental expression of Meltrin beta  to that of ADAM 13. A PCR sequence tag generated from X. laevis was found to be 74% identical to Meltrin alpha , making it unlikely that Meltrin alpha  and ADAM 13 are orthologues (18). Because a similarly high level of sequence conservation has also been observed between mouse and X. laevis Mdc9 (75% sequence similarity) and between human MDC11 and X. laevis Mdc11 (72% sequence similarity),2 other potential orthologues may be equally well conserved. For this reason, Meltrin beta  was considered to likely be a novel metalloprotease-disintegrin protein and was therefore assigned the number 19 in the ADAM numbering system (see Ref. 1).3

To obtain some insight into the potential functions of meltrin alpha , meltrin beta , mdc9, and mdc15 in bone, we analyzed the expression levels of these four MDC genes in bone cells. The full-length sequences of mouse Mdc9, human MDC9 (14), mouse Meltrin alpha  (6), and human MDC15 (15) have been previously reported. Because mouse bone cells were used here, mouse Mdc15 cDNA4 was used for RNase protection experiments. Mouse Mdc15 is 79.7% identical to human MDC15 at the amino acid level, is widely expressed, and, interestingly, contains the sequence TDD instead of RGD in the predicted integrin binding sequence. All four MDC proteins analyzed here contain a metalloprotease domain with a predicted catalytic site, a disintegrin domain, and cytoplasmic domains with predicted signaling motifs, including SH3 ligand domains. Other features of potential functional significance shared by the four MDC proteins include a predicted subtilisin type proprotein convertase cleavage site (RX(K/R)R) between the prodomain and the metalloprotease domain (38, 39) and an odd-numbered cysteine in the prodomain that most likely is involved in a cysteine switch regulation of the protease (40, 41).

Our results demonstrate that in bone, the major cell type expressing meltrin alpha  and meltrin beta  is the osteoblast. It is now well established that osteoblasts originate from mesenchymal stem cells, which also give rise to myocytes, chondrocytes, and adipocytes. For example, several clonal cell lines of mesenchymal origin have been reported to be able to differentiate into two or more distinct cell types under appropriate conditions (42, 43). Although it is yet to be determined whether or not meltrin alpha  and meltrin beta  are expressed in chondrocytes and adipocytes, the relatively restricted pattern of expression in myoblasts and osteoblasts implies that they may play key roles in differentiation and/or functions of mesenchymal cells in connective tissues. Further evidence for potential functions of the meltrins in bone can be derived from our findings that the expression of meltrin alpha  and meltrin beta  is regulated during osteoblast differentiation in vitro and that expression of meltrin beta  in primary osteoblasts is inducible by calcitriol, an active metabolite of vitamin D3. Osteoblasts are known to express receptors for vitamin D, and calcitriol has been shown to have various direct effects on both primary osteoblasts and osteoblastic cell lines (44). Vitamin D is one of the major regulators of bone and mineral metabolism, as evidenced by the fact that lack of vitamin D action causes clinical disorders such as osteomalacia and rickets due to a mineralization defect (reviewed in Ref. 44). Collectively, our results suggest a link between osteoblast differentiation and the expression of meltrin alpha  and meltrin beta . It should, however, be noted that the cells used in this study, mouse calvarial cells and MC3T3E1 cells, may not represent normal osteoblast populations in every aspect. For example, calcitriol has inhibitory effects on osteocalcin expression in mouse calvarial cells, as opposed to stimulatory effects observed in rat and human osteoblasts (45). Furthermore, it is known that in vitro differentiation of MC3T3E1 cells may differ from primary osteoblasts because they express very little, if any, of the transcription factor Msx-2 during the proliferative stage (46).

Based on what is known about other metalloprotease-disintegrin proteins, we predict that the meltrins may function in cell adhesion and/or signaling between osteoblasts or may be involved in protein ectodomain cleavage or shedding of osteoblast proteins that may require processing for activity (13). Preliminary studies with MC3T3E1 cells that were stably transfected with meltrin beta failed to reveal any changes in the expression of osteoblastic genes, such as type 1 collagen and osteocalcin, when compared with vector-transfected control cells (data not shown). Clearly, further study, such as the analysis of the function of individual protein domains of the meltrins, and targeted gene knockout experiments will be necessary to clarify the physiological role of meltrin alpha  and meltrin beta  in osteoblasts.

Osteoclasts, another major type of bone cells, are terminally differentiated, multinucleated bone-resorbing cells that originate in multipotent hematopoietic stem cells and belong to the monocyte/macrophage lineage (reviewed in Refs. 36 and 47). RNase protection assays suggest that osteoclasts express only mdc9 and mdc15, but not meltrin alpha  or meltrin beta , whereas osteoblasts express all four MDC genes. This would argue against a role of meltrin alpha  and meltrin beta  in osteoclast fusion, although an expression in fusing osteoclasts that is down-regulated immediately after fusion cannot be ruled out with the assay used here. Although the level of mdc9 and mdc15 expression observed in purified mature OCLs was considerably lower than that found in osteoblasts and cocultures, it seems unlikely that the expression of meltrin alpha  and meltrin beta  observed here is due to contamination with other cells because we were not able to detect meltrin alpha  and meltrin beta  expression in the OCL RNA samples, even after longer exposure (data not shown). Thus, our results suggest that mdc9 and mdc15 are expressed in cells of the osteoclast lineage, although their expression in osteoclast precursors remains to be verified by single-cell level analyses.

For an initial biochemical characterization of Meltrin beta , antibodies against the cytoplasmic tail were raised and used in a Western blot analysis of COS-7 cell expressing Meltrin beta , of mouse C2C12 cells, and of mouse POB cells. In all three cases, the predominant form of Meltrin beta  has a molecular mass of 115 kDa, which is ~15 kDa larger than the predicted molecular mass of 99.72 kDa of Meltrin beta  after removal of the signal sequence. This band most likely corresponds to a glycosylated form of Meltrin beta , in which the prodomain and metalloprotease domain are membrane-anchored. A band of 85 kDa, which is relatively more abundant in POBs, probably corresponds to a form of Meltrin beta  in which the prodomain has been removed but the metalloprotease domain is still attached. The less prominent bands of 42 and 35 kDa most likely represent shorter proteolytically processed forms of Meltrin beta . Although the functional significance of these processed forms remains to be determined, for fertilin beta  and for Meltrin alpha , there is evidence that removal of the metalloprotease domain may regulate a role in membrane binding and/or fusion (3, 6, 13).

In summary, we have cloned the full-length cDNA of mouse meltrin beta  and demonstrated that meltrin beta  and three other members of the MDC gene family, meltrin alpha , mdc9, and mdc15, are expressed in bone cells. The finding that meltrin alpha  and meltrin beta  are highly expressed in osteoblasts and are regulated by vitamin D and during osteoblast differentiation suggests that these two proteins may play a role in bone formation. Our results further show that meltrin alpha , which was previously implicated in muscle fusion, is apparently not expressed in mature osteoclasts. Further study will be necessary to dissect the role of the metalloprotease domain, the disintegrin domain, and the cytoplasmic signaling motifs of these MDC gene products in bone metabolism.

    ACKNOWLEDGEMENT

We thank J. Leibow for excellent technical assistance.

    FOOTNOTES

* This work was funded in part by grants to C. P. B. (National Institutes of Health R55GM51988 and National Science Foundation MCB-9631601), by Memorial Sloan-Kettering Cancer Center Support Grant NCI-P30-CA-08748, and by a grant from Hoechst Marion Roussel (Roussel-Uclaf, France), to R. B.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF019887.

§ Present address: University of Tokushima, School of Medicine, First Department of Internal Medicine, 3-18-15 Kuramoto-cho Tokushima-shi, Tokushima 770, Japan.

par Present address: Institute of Cellular and Molecular Biology, Research Laboratories of Schering AG, D-13342 Berlin, Germany.

** To whom correspondence should be addressed: Cellular Biochemistry and Biophysics Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Box 368, 1275 York Ave., New York, NY 10021. Tel.: 212-639-2915; Fax: 212-717-3047; E-mail: c-blobel{at}ski.mskcc.org.

1 The abbreviations used are: MDC, metalloprotease, disintegrin, and cysteine-rich domains; OCL, osteoclast-like cell; PCR, polymerase chain reaction; GST, glutathione S-transferase; POB, primary osteoblast.

2 H. Cai, J. Krätzschmar, and C. Blobel, manuscript in preparation.

3 J. White, personal communication.

4 L. Lum and C. Blobel, manuscript in preparation.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Wolfsberg, T. G., and White, J. M. (1996) Dev. Biol. 180, 389-401[CrossRef][Medline] [Order article via Infotrieve]
  2. Primakoff, P., Hyatt, H., and Tredick-Kline, J. (1987) J. Cell Biol. 104, 141-149[Abstract]
  3. Blobel, C. P., Myles, D. G., Primakoff, P., and White, J. M. (1990) J. Cell Biol. 111, 69-78[Abstract]
  4. Blobel, C. P., Wolfsberg, T. G., Turck, C. W., Myles, D. G., Primakoff, P., White, J. M. (1992) Nature 356, 248-252[CrossRef][Medline] [Order article via Infotrieve]
  5. Myles, D. G., Kimmel, L. H., Blobel, C. P., White, J. M., Primakoff, P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4195-4198[Abstract]
  6. Yagami-Hiromasa, T., Sato, T., Kurisaki, T., Kamijo, K., Nabeshima, Y., and Fujisawa-Sehara, A. (1995) Nature 377, 652-656[CrossRef][Medline] [Order article via Infotrieve]
  7. Fambrough, D., Pan, D., Rubin, G. M., Goodman, C. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13233-13238[Abstract/Free Full Text]
  8. Rooke, J., Pan, D., Xu, T., and Rubin, G. M. (1996) Science 273, 1227-1230[Abstract]
  9. Pan, D., and Rubin, J. (1997) Cell 90, 271-280[Medline] [Order article via Infotrieve]
  10. Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Cartner, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Lessnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J.-L., Warner, J., Willard, D., Becherer, J. D. (1997) Nature 385, 733-736[CrossRef][Medline] [Order article via Infotrieve]
  11. Black, R., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K. A., Gerhart, M., Davis, R., Fitzner, J. N., Johnson, R. S., Paxton, R. J., March, C. J., Cerretti, D. P. (1997) Nature 385, 729-733[CrossRef][Medline] [Order article via Infotrieve]
  12. Blaumueller, C. M., Qi, H., Zagouras, P., and Artavanis-Tsakonas, S. (1997) Cell 90, 281-291[Medline] [Order article via Infotrieve]
  13. Blobel, C. P. (1997) Cell 90, 589-592[CrossRef][Medline] [Order article via Infotrieve]
  14. Weskamp, G., Krätzschmar, J. R., Reid, M., and Blobel, C. P. (1996) J. Cell Biol. 132, 717-726[Abstract]
  15. Krätzschmar, J., Lum, L., and Blobel, C. P. (1996) J. Biol. Chem. 271, 4593-4596[Abstract/Free Full Text]
  16. Herren, B., Raines, E. W., and Ross, R. (1997) FASEB J. 11, 173-180[Abstract/Free Full Text]
  17. Podbilewicz, B. (1996) Mol. Biol. Cell 7, 1877-1893[Abstract]
  18. Alfandari, D., Wolfsberg, T. G., White, J. M., DeSimone, D. W. (1997) Dev. Biol. 182, 314-330[CrossRef][Medline] [Order article via Infotrieve]
  19. Shilling, F. M., Krätzschmar, J., Cai, H., Weskamp, G., Gayko, U., Leibow, J., Myles, D. G., Nuccitelli, R., Blobel, C. P. (1997) Dev. Biol. 186, 155-164[CrossRef][Medline] [Order article via Infotrieve]
  20. Weskamp, G., and Blobel, C. P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2748-2751[Abstract]
  21. Wolfsberg, T. G., Straight, P. D., Gerena, R. L., Huovila, A.-P. J., Primakoff, P., Myles, D. G., White, J. M. (1995) Dev. Biol. 169, 378-383[CrossRef][Medline] [Order article via Infotrieve]
  22. Wolfsberg, T. G., Bazan, J. F., Blobel, C. P., Myles, D. G., Primakoff, P., White, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10783-10787[Abstract]
  23. Emi, M., Katagiri, T., Harada, Y., Saito, H., Inazawa, J., Ito, I., Kasumi, F., and Nakamura, Y. (1993) Nat. Genet. 5, 151-157[Medline] [Order article via Infotrieve]
  24. Evans, J. P., Schultz, R. M., and Kopf, G. S. (1995) J. Cell Sci. 108, 3267-3278[Abstract/Free Full Text]
  25. Almeida, E. A. C., Huovila, A.-P. J., Sutherland, A. E., Stephens, L. E., Calarco, P. G., Shaw, L. M., Mercurio, A. M., Sonnenberg, A., Primakoff, P., Myles, D. G., White, J. M. (1995) Cell 81, 1095-1104[Medline] [Order article via Infotrieve]
  26. Yuan, R., Primakoff, P., and Myles, D. G. (1997) J. Cell Biol. 137, 105-112[Abstract/Free Full Text]
  27. Huovila, A.-P. J., Almeida, E. A. C., White, J. M. (1996) Curr. Opin. Cell Biol. 8, 692-699[CrossRef][Medline] [Order article via Infotrieve]
  28. Yaffe, D., and Saxel, O. (1977) Nature 270, 725-727[Medline] [Order article via Infotrieve]
  29. Krätzschmar, J., Haendler, B., Langer, G., Boidol, W., Bringmann, P., Alagon, A., Donner, P., and Schleuning, W. D. (1991) Gene 105, 229-237[Medline] [Order article via Infotrieve]
  30. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
  31. Yamin, M., Gorn, A. H., Flannery, M. R., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Tapp, D. R., Krane, S. M., Goldring, S. R. (1994) Endocrinology 135, 2635-2643[Abstract]
  32. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, pp. 53-138, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY
  33. Sudo, H., Kodama, H. A., Amagai, Y., Yamamoto, S., and Kasai, S. (1983) J. Cell Biol. 96, 191-198[Abstract]
  34. Takahashi, N. T., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., Suda, T. (1988) Endocrinology 123, 2600-2602[Abstract]
  35. Minkin, C. (1982) Calcif. Tissue Int. 34, 285-290[Medline] [Order article via Infotrieve]
  36. Suda, T., Takahashi, N., and Martin, T. J. (1992) Endocr. Rev. 13, 66-80[Medline] [Order article via Infotrieve]
  37. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  38. Fuller, R. S., Brake, A. J., and Thorner, J. (1989) Science 246, 482-486[Medline] [Order article via Infotrieve]
  39. Chretien, M., Mbikay, M., Gaspar, L., and Seidah, N. G. (1995) Proc. Assoc. Am. Phys. 107, 47-66[Medline] [Order article via Infotrieve]
  40. Birkedal-Hansen, H. (1995) Curr. Opin. Cell Biol. 7, 728-735[CrossRef][Medline] [Order article via Infotrieve]
  41. Woessner, J. F. (1991) FASEB J. 5, 2145-2154[Abstract/Free Full Text]
  42. Grigoriadis, A. E., Heersche, J. N. M., Aubin, J. E. (1988) J. Cell Biol. 106, 2139-2151[Abstract]
  43. Katagiri, T. (1994) J. Cell Biol. 127, 1755-1766[Abstract]
  44. Reichel, H., Koeffler, H. P., and Norman, A. W. (1989) N. Engl. J. Med. 320, 980-991[Medline] [Order article via Infotrieve]
  45. Zhang, R., Ducy, P., and Karsenty, G. (1997) J. Biol. Chem. 272, 110-116[Abstract/Free Full Text]
  46. Towler, D. A., Rutledge, S. J., and Rodan, G. A. (1994) Mol. Endocrinol. 8, 1484-1493[Abstract]
  47. Roodman, G. D. (1996) Endocr. Rev. 17, 308-332[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.